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TO THE EDITOR
Dapsone (4,40-diaminodiphenylsulfone)
has been widely used in the treatment
of leprosy since its discovery in the
1940s, and some of its reported side
effects include methemoglobinemia,
hemolysis, agranulocytosis, and dap-
sone-induced hypersensitivity reactions
(DIHRs) (Zhu and Stiller, 2001). DIHR is
a life-threatening drug reaction, which
has been reported in B2% of leprosy
patients on dapsone therapy; thus, with
12.5% mortality, DIHR is one of the
major causes of mortality in leprosy
patients (Pandey et al., 2007; Shen
et al., 2011). DIHR is clinically mani-
fested through fever, rash, lymphadeno-
pathy, and hepatitis, and is categorized
under the drug-induced hypersensitivity
or drug rash with eosinophilia and
systemic symptoms syndromes (Sener
et al., 2006; Kardaun et al., 2007;
Kumari et al., 2011). Unlike other drug
reactions, DIHR usually presents with
low hemoglobin and a higher risk of
liver involvement, including cholestatic
or hepatocellular disease, or both
(Richardus and Smith, 1989; Zhu and
Stiller, 2001).
Although the exact mechanism of
DIHR remains unclear, numerous
reports have described the associations
between human leukocyte antigens
(HLA, especially MHCI) and drug
eruptions in patients with various dis-
eases (Mallal et al., 2002; Chung et al.,
2004; Pavlos et al., 2012). Some HLA
profiles are useful tools in diagnosing
and preventing life-threatening adverse
drug reactions (Chung et al., 2004;
Mallal et al., 2008). Dapsone is meta-
bolized through acetylation and
N-hydroxylation. Genetic polymorph-
ism of human NAT2 determining slow
acetylator status is a predisposing factor
for allergic diseases and drug adverse
reactions (Zielinska et al., 1998;
Gawronska-Szklarz et al., 1999).
Cytochrome P450 2C9 (CYP2C9) has
also been shown to be the initial step
in the formation of toxic intermediate
metabolites of sulfonamides, which are
analogs of dapsone, that can induce
hemolytic anemia and skin rash (Winter
et al., 2000; Wolkenstein et al., 2005).
We performed a case–control
study from June 2009 to June 2012 in
Southern China and screened 1058
cases of leprosy patients. Among them,
21 cases (1.98%) met the enrollment
criteria for DIHR according to
Richardus and Smith’s (1989) criteria;
105 dapsone-tolerant control cases were
also studied, defined as leprosy patients
with more than 8 weeks of exposure
to dapsone but without any episode of
drug eruption and reaction. In addition,
100 non-leprosy control individuals
were recruited from local community
blood donors. The socio-demographic
characteristics of the DIHR patients,Accepted article preview online 19 April 2013; published online 16 May 2013
Abbreviations: AUC, area under the curve; CYP2C9, cytochrome P450 2C9; DIHR, dapsone-induced
hypersensitivity reaction; HLA, human leukocyte antigen; MHC, major histocompatibility complex; NAT2,
N-acetyltransferase2
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dapsone-tolerant patients, and healthy
controls are summarized in Table 1
(Supplementary Table S1 online). No
significant difference was observed in
terms of age, sex, and ethnicity among
the three groups (age: P¼0.713, sex:
P¼1.000, ethnicity: P¼ 1.000). Patients
presented with clinical signs of DIHR at
a median of 28±8.5 days after starting
dapsone. The most common documen-
ted clinical signs of DIHR were fever
(100%) and rash (100%). Of the 21
cases, 15 (71.4%) and 6 (28.6%) cases
presented with maculopapular eruptions
and vesiculopapules, respectively. Lym-
phadenopathy was noted in 16 (76.2%)
cases. The abnormal laboratory profiles
involved elevated levels of serum liver
enzymes and hypoalbuminemia in all
cases, as well as low hemoglobin, leu-
kocytosis, and eosinophilia in 18
(85.7%), 18 (85.7%), and 10 cases
(47.6%), respectively. Cessation of dap-
sone therapy was recommended by
local doctors upon suspecting DIHR;
the patients were then treated with
systemic corticosteroids at average
doses of 0.5 to 1 mg kg 1 of predniso-
lone, and their skin eruptions subsided
on an average of 21.6±8.7 days.
Major histocompatibility complex
(MHC) I region typing and gene poly-
morphisms of related metabolism
enzymes were detected in 122 leprosy
patients exposed to dapsone and
96 healthy controls (Supplementary
Materials and Methods online). HLA-
B*1301 and HLA-Cw*0304 were pre-
sent in significantly higher frequencies
in DIHR patients than in either dapsone-
tolerant patients or healthy controls
(Table 2; Supplementary Table S2
online). Particularly, HLA–B*1301 was
found in 90% of DIHR patients and was
present in only 6.9% of dapsone-toler-
ant patients, with a sensitivity and spe-
cificity of 90 and 93.1%, respectively
(AUC: 0.92). If either HLA-B*1301 or
HLA B*1313 was present, the sensitivity
and specificity were 100 and 92.2%,
respectively (AUC: 0.961). The most
common of these three-locus MHC
I-combined haplotypes in DIHR patients
was HLA-A*1101-B*1301-Cw*0304
(68.4%); however, it was present in only
1% of dapsone-tolerant patients. Among
DIHR and dapsone-tolerant patients,
the presence of HLA-B*1301 and HLA-
C*0304 alleles had a positive predictive
Table 1. Demographic data for the cases and controls
Variable
Leprosy patients
with DIHR
(n¼21)
DDS-tolerant
leprosy patients
(n¼105)
Healthy
controls1
(n¼ 100)
Age (years mean±SD) 38.2±11.7 40.3±11.8 39.5±10.7
Male (no. (%)) 11 (52.4%) 55 (52.4%) 53 (53.0%)
Female (no. (%)) 10 (47.6%) 50 (47.6%) 47 (47%)
DDS-exposure duration (weeks) o8 48 
Han Chinese 12 (57.1%) 55 (52.4%) 52 (52.0%)
Non-Han Chinese 9 (42.9%) 50 (47.6%) 48 (48.0%)
Miao group 4 (19.0%) 22 (21.0%) 20 (20.0%)
Tu group 2 (9.5%) 12 (11.4%) 12 (12.0%)
Zhuang group 2 (9.5%) 12 (11.4%) 12 (12.0)
Buyi group 1 (4.8%) 4 (3.8%) 4 (4.0%)
Abbreviations: DDS, diamino diphenyl sulphone (dapsone); DIHR, dapsone-induced hypersensitivity
reaction.
1Healthy controls: healthy non-leprosy controls not exposed to dapsone.
Table 2. Frequency of HLA alleles in cases and controls
HLA allele
Leprosy patients
with DIHR
(n¼ 20)
DDS-tolerant
leprosy patients
(n¼ 102)
Healthy
controls1
n¼96)
OR
(95% CI) pc
B*1301 18 (90%) 7(6.9%) 11(11.5%) 122.1 (23. 5–636.2)2
69.6 (14.2–341.0)3
6.038 1012 2
1.961 1011 3
B*1313 2 (10%) 1 (1.0%) 0 (0%)
C*0304 19 (95%) 22 (21.6%) 24 (25%)
B*1301, C*0304 17 (85%) 6 (5.9%)2 4 (4.2%) 90.667 (20.7–397. 8)2 4.280 1011 2
B*1301 or B*1313 20 (100%) 8 (7.9%)2 11 (11.5%)3 470.0 (25.9–8521.3)2
154.6 (18.8–1267.4)3
8.320 1015 2
4.040 1013 3
A*11:01, B*13:01, C*03:04 13 (68.4%, n¼ 19) 3 (3.0%, n¼ 101)4 70. 8 (15.8–317.8)2
216.7 (24.1–1944.6)5
1.668 108 2
4.644 1010 5
Abbreviations: CI, confidence interval; DDS, diamino diphenyl sulphone (dapsone); DIHR, dapsone-induced hypersensitivity reaction; HLA, human leukocyte
antigen; OR, odds ratio.
1Healthy controls: healthy non-leprosy controls not exposed to dapsone.
2Cases/dapsone-tolerant controls.
3Cases/healthy controls.
4Failure in genotyping for HLA A in 1 leprosy patient with DIHR and 1 DDS-tolerant leprosy patient.
5Cases/dapsone-tolerant controls (analysis of the haplotype of linkage disequilibrium for HLA-A*1101-B*1301-Cw*0304).
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value for DIHR (76%), and the absence
of this combination of alleles had a
negative predictive value of 99.0%,
whereas the presence of the HLA-
B*1301 haplotype alone was associated
with positive (72.0%) and negative
(97.9%) predictive values for DIHR. No
significant association was observed
among any of the genotypes or pheno-
types of CYP2C9 (including the
single-nucleotide polymorphisms of its
promoter) and NAT2 with occurrence of
DIHR.
The current study proposes that the
presence of the HLA-B*1301 haplotype
is strongly associated with DIHR devel-
opment, supporting an important and
immediately applicable clinical role for
HLA typing in this setting. However,
several limitations are present. First,
although the study was carried out in
several geographical areas in China,
further studies among patients with dif-
ferent ethnic backgrounds are needed.
Second, the sample size may not be
large enough for the subgroup analysis
to show potential associations between
HLA alleles and subgroups of DIHR,
even though current data showed statis-
tical significance and a strong associa-
tion between HLA-B*1301 and DIHR.
Third, given the difficulty of sample
collection, non-leprosy patients with
DIHR and other dapsone-related side
effects were not investigated in this
study; confirmation as to whether the
findings in leprosy patients can be used
for non-leprosy patients with DIHR is
still required.
In summary, HLA-B*1301 can be a
useful biomarker in predicting DIHR
before administering dapsone to
leprosy patients in the Chinese popula-
tion. DIHR mechanism appears to be
immunologically related to HLA, but
not to dapsone metabolism. Further
studies are needed to investigate the
molecular mechanisms of HLA sub-
types and DIHR in leprosy patients.
A large-scale prospective study is also
necessary to verify the value of HLA-
B*1301 as a predictive biomarker for
DIHR. Nevertheless, our results pro-
vide plausible basis for predicting
DIHR in dapsone-exposed leprosy
cases, and have implications for further
scientific research and control of DIHR
in leprosy.
The study was approved by the Med-
ical Ethics Committee of the Chinese
Academy of Medical Sciences Institute
of Dermatology in Nanjing [KYZR2009-
016], and written, informed consent was
obtained from all participants.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This study was supported by grants from the
National Natural Science Foundation of China
(No. 30972651) and the Research Special Fund
for Public Welfare Industry of Health of China
(No. 201002016), as well as by funding from the
Key Clinical Program of the Ministry of Health
of China (No. 2010-2012-125). Support for the
HLA analyses was provided by Liming Wu and
Ruixiao Ma.
DISCLAIMER
The sponsor of the study had no role in the study
design, data collection, data analysis, data inter-
pretation, or manuscript preparation. HW and LY
had full access to data collected for the study, and
BW and HW had final responsibility and decision
for publication submission.
Hongsheng Wang1,2, Liangbin Yan1,2,
Guocheng Zhang1,2, Xiangsheng Chen1,2,
Jun Yang3, Ming Li4, Jianping Shen1,2,
Meiwen Yu1,2, Ran Huo5 and
Baoxi Wang1,2
1Institute of Dermatology, Chinese Academy of
Medical Sciences, National Center for STD and
Leprosy Control, China CDC, Nanjing, China;
2Jiangsu Key Laboratory of Molecular Biology
for Skin Diseases and STIs, Nanjing, China;
3Yunnan Provincial CDC, Yunnan, China;
4Guangdong Provincial Dermatology Hospital,
Guangdong, China and 5Miller School of
Medicine, University of Miami, Miami,
Florida, USA
E-mail: wangbx@ncstdlc.org
The work was conducted in Nanjing, Jiangsu
Province, China.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
REFERENCES
Chung WH, Hung SI, Hong HS et al. (2004)
Medical genetics; a marker for Stevens-John-
son syndrome. Nature 428:486
Gawronska-Szklarz B, Luszawska-Kutrzeba T,
Czaja-Bulsa G et al. (1999) Relationship
between acetylation polymorphism and risk of
atopic diseases. Clin Pharmacol Ther 65:
562–9
Kardaun SH, Sidoroff A, Valeyrie-Allanore L et al.
(2007) Variability in the clinical pattern
of cutaneous side-effects of drugs with
systemic symptoms: does a DRESS syn-
drome really exist? Br J Dermatol 156:
609–11
Kumari R, Timshina DK, Thappa DM (2011) Drug
hypersensitivity syndrome. Indian J Dermatol
Venereol Leprol 77:7–15
Mallal S, Nolan D, Witt C et al. (2002) Association
between presence of HLA-B*5701, HLA-DR7,
and HLA-DQ3 and hypersensitivity to
HIV-1 reverse-transcriptase inhibitor abacavir.
Lancet 359:727–32
Mallal S, Phillips E, Carosi G et al. (2008) HLA-
B*5701 screening for hypersensitivity to aba-
cavir. N Engl J Med 358:568–79
Pandey B, Shrestha K, Lewis J et al. (2007)
Mortality due to dapsone hypersensi-
tivity syndrome complicating multi-drug
therapy for leprosy in Nepal. Trop Doct 37:
162–3
Pavlos R, Mallal S, Phillips E (2012) HLA and
pharmacogenetics of drug hypersensitivity.
Pharmacogenomics 13:1285–306
Richardus JH, Smith TC (1989) Increased incidence
in leprosy of hypersensitivity reactions to
dapsone after introduction of multidrug
therapy. Lepr Rev 60:267–73
Sener O, Doganci L, Safali M et al. (2006) Severe
dapsone hypersensitivity syndrome. J Investig
Allergol Clin Immunol 16(4):268–70
Shen J, Liu M, Zhou M, Li W (2011) Causes of
death among active leprosy patients in China.
Int J Dermatol 50:57–60
Winter HR, Wang Y, Unadkat JD (2000) CYP2C8/9
mediate dapsone N-hydroxylation at clinical
concentrations of dapsone. Drug Metab
Dispos 28:865–8
Wolkenstein P, Loriot MA, Flahault A et al. (2005)
Association analysis of drug metabolizing
enzyme gene polymorphisms in AIDS patients
with cutaneous reactions to sulfonamides.
J Invest Dermatol 125:1080–2
Zhu YI, Stiller MJ (2001) Dapsone and sulfones in
dermatology: overview and update. J Am
Acad Dermatol 45:420–34
Zielinska E, Niewiarowski W, Bodalski J (1998)
The arylamine N-acetyltransferase (NAT2)
polymorphism and the risk of adverse reac-
tions to co-trimoxazole in children. Eur J Clin
Pharmacol 54:779–85
H Wang et al.
Association between HLA-B*1301 and Dapsone-Induced Hypersensitivity Reactions
2644 Journal of Investigative Dermatology (2013), Volume 133
